This marked the first CAR-T cell-based treatment for an autoimmune disease, and additional clinical trials using anti-CD19/BCMA CAR-T cells or anti-CD19 CAR-T cells for relapsed/refractory SLE are currently ongoing (97). Here, CD19 is linked to systemic lupus erythematosus.